Teratogen update: Pseudoephedrine
- 1 June 2006
- journal article
- review article
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 76 (6) , 445-452
Abstract
Pseudoephedrine is contained in decongestants such as the Sudafed line of products. It is an alpha‐adrenergic receptor agonist, which causes blood vessel constriction, including the therapeutic effect of reducing airflow resistance in the nasal cavity. Pseudoephedrine is one of the most commonly used medications in pregnancy, with an estimated 25% of women exposed. It has been demonstrated that alpha‐adrenergic receptor agonists slow uterine blood flow, but their effects have not been studied in relation to most reproductive outcomes in animals or humans. Two analyses of health maintenance organization pharmacy data identified 9 malformed infants among 902 first‐trimester pseudoephedrine exposures, suggesting no association with birth defects overall; however, studies of such data sets often lack sufficient power to identify risks for specific birth defects. The related compounds, epinephrine, ephedrine, and phenylephrine, have been associated with hemorrhages and cardiovascular and limb malformations in animal models. Risk of ventricular septal defects was associated with decongestant use in pregnant women in 1 recent study. The vasoconstrictive effects of these drugs raise the hypothesis that their use in early pregnancy might increase the risk of vascular disruption defects. Case‐control studies, which often do have power to identify risks related to specific birth defects, have explored this hypothesis. Decongestant use in the first trimester has been associated with small increases in risks of 3 defects thought to arise, at least in some instances, from vascular disruption–gastroschisis, small intestinal atresia, and hemifacial microsomia. These findings are somewhat consistent in terms of magnitude of effect and suggest that risks are even greater among women also exposed to the vasoconstrictive effects of cigarette smoking. There are, however, limitations to these studies, including the possibilities of inaccurate recall of exposures and confounding by indication. In addition, the majority of decongestant use is in oral form and the question of whether intranasal formulations carry risk has not been adequately addressed. Birth Defects Research (Part A) 76:445–452, 2006.Keywords
This publication has 62 references indexed in Scilit:
- Use of oral decongestants during pregnancy and delivery outcomeAmerican Journal of Obstetrics and Gynecology, 2006
- Use of over-the-counter medications during pregnancyAmerican Journal of Obstetrics and Gynecology, 2005
- Urethral obstruction sequence and lower limb deficiency: Evidence for the vascular disruption hypothesisThe Journal of Pediatrics, 1993
- Vascular pathogenesis of unilateral craniofacial defectsThe Journal of Pediatrics, 1987
- Congenital Heart Disease in Relation to Maternal Use of Bendectin and Other Drugs in Early PregnancyNew England Journal of Medicine, 1985
- Vascular pathogenesis of transverse limb reduction defectsThe Journal of Pediatrics, 1982
- The vascular pathogenesis of gastroschisis: Intrauterine interruption of the omphalomesenteric arteryThe Journal of Pediatrics, 1981
- Monozygotic twinning and structural defectsThe Journal of Pediatrics, 1979
- Congenital malformations in nonhuman primates: Spontaneous and experimentally inducedThe Anatomical Record, 1967
- Influence of Currents on Form of SpongesScience, 1960